MUVON Therapeutics is a Swiss biotechnology start-up with the goal of developing and commercializing an autologous cell therapy for the regeneration of skeletal muscle tissue, focusing initially on the treatment of stress urinary incontinence.
Location: Switzerland
Employees: 11-50
Founded date: 2020
Investors 1
| Date | Name | Website |
| 09.05.2023 | VentureLab | venturelab... |
Mentions in press and media 27
| Date | Title | Description |
| 16.03.2026 | SEF.WomenAward 2026: Gewinnerinnen gekürt | Das Swiss Economic Forum (SEF) ehrt mit dem SEF.WomenAward jedes Jahr drei Frauen für ihre herausragenden unternehmerischen Leistungen. Verliehen werden die Preise in den Kategorien «Jungunternehmerin des Jahres» sowie «Unternehmerin/CEO d... |
| 18.12.2025 | Executive reshuffle in ICT and Biotech startups | Payment provider Payrexx AG has appointed Anja Traum to the position of CEO effective 1 January 2026 to guide the company through its upcoming expansion phase. With a team of 50 employees, a transaction volume of CHF 1 billion, and average... |
| 03.12.2025 | Four biotech startups reach key milestones | MUVON Therapeutics AG, which is focused on the treatment of stress urinary incontinence (SUI) in women, has achieved positive topline results from the Phase 2 clinical trial SUISSE-MPC2 (NCT05534269) evaluating its novel proprietary muscle... |
| 25.11.2025 | SEF.WomenAward 2026: Diese drei Gründerinnen stehen im Finale | Die von NZZ Connect organisierte Auszeichnung würdigt Unternehmerinnen, Gründerinnen und Geschäftsführerinnen, die mit visionärer Führung und innovativem Unternehmertum überzeugen. Verliehen werden Preise in den Kategorien «Jungunternehmer... |
| 21.07.2025 | Drei Startups verstärken ihre Verwaltungsräte | Das Zürcher Food-Startup kaisin. kann neu auf das Wissen, die Erfahrungen und Kompetenzen von Bettina Heinzmann im Verwaltungsrat zählen. Heinzmann, Mitgründerin des Women in Retail Switzerland + Friends Netzwerks, bringe breites Fachwisse... |
| 23.04.2025 | A New Dawn in Cancer Treatment: Onward Therapeutics' Bold Move with NK Cell Therapy | In the world of biotechnology, breakthroughs often feel like whispers in a storm. Yet, some announcements resonate like thunder. Onward Therapeutics has just made such a declaration. The company, rooted in Switzerland, is stepping into the ... |
| 23.04.2025 | Swiss biotechs on track to address key medical challenges | Onward Therapeutics SA is focused on advancing innovative cancer immunotherapies through a fast-track development model. Its portfolio includes a bispecific antibody (OT-A201) licensed from Biomunex, alongside an equity investment; and an ... |
| 31.03.2025 | BioEntrepreneurship: Catalyzing innovation from Lab to market | Swiss universities are innovation hubs, where novel ideas are born with the potential to address critical global challenges. Yet, without the right support, many of these promising concepts remain confined to the lab. The Institute of Rege... |
| 09.01.2025 | MUVON Therapeutics Clears Phase 2 Interim Milestone and Will Participate in the 2025 J.P. Morgan Healthcare Conference | MUVON Therapeutics Clears Phase 2 Interim Milestone and Will Participate in the 2025 J.P. Morgan Healthcare Conference Thu, Jan 09, 2025 10:12 CET Report this content PRESS RELEASE Zurich, Switzerland, January 9, 2025 – MUVON Therapeutics A... |
| 06.11.2023 | A decent representation at BIO-Europe |
Show more